Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the regulatory approval and launch of GRASTEKĀ®
(Timothy grass pollen allergen extract) sublingual tablets in Canada.
This represents the first approval of GRASTEK for Merck. The product is
currently marketed by ALK-Abello in Europe as GRAZAX.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news